New hope for aggressive lymphoma: triple-drug combo enters human trials
NCT ID NCT07643805
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new combination of drugs for adults with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to previous treatment. About 46 participants will receive an experimental drug (EZH2 inhibitor) along with two other drugs (glofitamab and chemotherapy). The goal is to see how many people achieve complete remission. This is an early-phase trial, so safety and effectiveness are still being evaluated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DLBCL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, 210029, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted pill boost Chemotherapy's punch against lymphoma?
- Real-World data may reveal how well tafasitamab fights Hard-to-Treat lymphoma
- Off-the-Shelf immune cells take on tough lymphoma
- New cocktail aims to tame aggressive lymphoma in the very elderly
- New drug cocktail aims to tackle tough lymphoma
- New drug cocktail targets Hard-to-Treat brain cancer